Media
News & Events
CurePSP awards a research grant to Asceneuron
CurePSP awards a research grant to Asceneuron to study the role of O-linked protein glycosylation in the spread of tau pathology.
Dr. J. Donald deBethizy appointed to the Asceneuron’s Board of Directors
Asceneuron today announced the appointment of Dr. J. Donald deBethizy to its board of directors.
Asceneuron presents the novel M1-targeting compound ASN-51
Asceneuron presents the novel M1-targeting compound ASN-51 at the 11th International Conference on Alzheimer's and Parkinson's disease held 6-10 March 2013 in Florence, Italy.
Merck Serono announces the creation of Asceneuron
Merck Serono announces the creation of Asceneuron, the third Spin-Off company from its entrepreneur Partnership Program. Asceneuron will develop Merck Serono’s research programs in the area of Alzheimer’s disease.
Asceneuron to attend BIO International Convention in Boston
The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA.
Asceneuron will present at AD/PD 2023
The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from March 28th to April 1st, in Gothenburg, Sweden.
Asceneuron to attend Bio-Europe Spring event
Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.
Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)
Asceneuron at the Annual Biotech in Europe Forum
Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on September 21st-22nd, 2022 in Basel.